Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Preferred Shares (2016 - 2025)

Guided Therapeutics' Preferred Shares history spans 13 years, with the latest figure at $817000.0 for Q3 2025.

  • For Q3 2025, Preferred Shares fell 2.51% year-over-year to $817000.0; the TTM value through Sep 2025 reached $817000.0, down 2.51%, while the annual FY2024 figure was $439000.0, 0.0% changed from the prior year.
  • Preferred Shares for Q3 2025 was $817000.0 at Guided Therapeutics, up from $438000.0 in the prior quarter.
  • Across five years, Preferred Shares topped out at $3.0 million in Q2 2021 and bottomed at $105000.0 in Q1 2021.
  • The 5-year median for Preferred Shares is $439000.0 (2022), against an average of $719555.6.
  • The largest annual shift saw Preferred Shares soared 1642.94% in 2021 before it plummeted 94.26% in 2022.
  • A 5-year view of Preferred Shares shows it stood at $3.0 million in 2021, then plummeted by 85.18% to $439000.0 in 2022, then changed by 0.0% to $439000.0 in 2023, then changed by 0.0% to $439000.0 in 2024, then skyrocketed by 86.1% to $817000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Preferred Shares are $817000.0 (Q3 2025), $438000.0 (Q2 2025), and $834000.0 (Q1 2025).